Carotid intima media thickness is associated with plasma lipoprotein-associated phospholipase A 2 mass in nondiabetic subjects but not in patients with type 2 diabetes

European Journal of Clinical Investigation

Volumn 41, Issue 8, 2011, Pages 820-827

  Constantinides, Alexander ^a,b   van Pelt, L Joost ^b   van Leeuwen, Jeroen J J ^b   de Vries, Rindert ^a   Tio, René A ^b   van der Horst, Iwan C C ^b   Sluiter, Wim J ^a   Dullaart, Robin P F ^a  

^a Department of Endocrinology ^*  (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Intima media thickness; Lipoprotein associated phospholipase A 2; Metabolic syndrome; Type 2 diabetes mellitus

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; PHOSPHOLIPASE A2;

ADULT; ARTICLE; BLOOD VESSEL PARAMETERS; CAROTID ARTERY; CAROTID INTIMA MEDIA THICKNESS; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TURBIDIMETRY;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; ATHEROSCLEROSIS; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; TUNICA INTIMA; TUNICA MEDIA;

EID: 79960095896     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02471.x     Document Type: Article

References (30)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
2. Caslake MJ, Packard CJ. Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. Nat Clin Pract Cardiovasc Med 2005;2:529-35.
3. Wilensky RL, Macphee CH. Lipoprotein-associated phospholipase A(2) and atherosclerosis. Curr Opin Lipidol 2009;20:415-20.
4. Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta 2009;1791:327-38.
5. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343:1148-55.
6. Persson M, Berglund G, Nelson JJ, Hedblad B. Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malmö, Sweden. Atherosclerosis 2008;200:191-8.
7. Tsimikas S, Willeit J, Knoflach M, Mayr M, Egger G, Notdurfter M et al. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur Heart J 2009;30:107-15.
8. Lp-PLA(2) Studies Collaboration, Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010;375:1536-44.
9. Casas JP, Ninio E, Panayiotou A, Palmen J, Cooper JA, Ricketts SL et al. PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. Circulation 2010;121:2284-93.
10. Schmidt MI, Duncan BB. Diabesity: an inflammatory metabolic condition. Clin Chem Lab Med 2003;41:1120-30.
11. Dullaart RPF, de Vries R, Sluiter WJ, Voorbij HA. High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus. Clin Endocrinol 2009;70:221-6.
12. Hatoum IJ, Hu FB, Nelson JJ, Rimm EB. Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes. Diabetes 2010;59:1239-43.
13. Iribarren C, Gross MD, Darbinian JA, Jacobs DR Jr, Sidney S, Loria CM. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler Thromb Vasc Biol 2005;25:216-21.
14. Kiortsis DN, Tsouli S, Lourida ES, Xydis V, Argyropoulou MI, Elisaf M et al. Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia. Angiology 2005;56:451-8.
15. Persson M, Nilsson JA, Nelson JJ, Hedblad B, Berglund G. The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis 2007;190:388-96.
16. Kardys I, Oei HH, van der Meer IM, Hofman A, Breteler MM, Witteman JC. Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol 2006;26:631-6.
17. Brilakis ES, Khera A, Saeed B, Banerjee S, McGuire DK, Murphy SA et al. Association of lipoprotein-associated phospholipase A2 mass and activity with coronary and aortic atherosclerosis: findings from the Dallas Heart Study. Clin Chem 2008;54:1975-81.
18. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfon SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular health study collaborative research group. N Engl J Med 1999;340:14-22.
19. Simera I, Moher D, Hoey J, Schultz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
20. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
21. Selzer RH, Hodis HN, Kwong-Fu H, Mack WJ, Lee PL, Liu CR et al. Evaluation of computerized edge tracking for quantifying intima-media thickness of the common carotid artery from B-mode ultrasound images. Atherosclerosis 1994;111:1-11.
22. Dullaart RPF, Groener JE, van Wijk H, Sluiter WJ, Erkelens DW. Alimentary lipemia-induced redistribution of cholesteryl ester between lipoproteins. Studies in normolipidemic, combined hyperlipidemic, and hypercholesterolemic men. Arteriosclerosis 1989;9:614-22.
23. Gomes MB, Cobas RA, Nunes E, Nery M, Castro-Faria-Neto HC, Tibiriçá E. Serum platelet-activating factor acetylhydrolase activity: a novel potential inflammatory marker in type 1 diabetes. Prostaglandins Other Lipid Mediat 2008;87:42-6.
24. Wootton PT, Stephens JW, Hurel SJ, Durand H, Cooper J, Ninio E et al. Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus. Atherosclerosis 2006;189:149-56.
25. Noto H, Chitkara P, Raskin P. The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes. J Diabetes Complications 2006;20:343-8.
26. Persson M, Hedblad B, Nelson JJ, Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol 2007;27:1411-6.
27. Wójcicka G, Jamroz-Wiśniewska A, Marciniak A, Łowicka E, Bełtowski J. The differentiating effect of glimepiride and glibenclamide on paraoxonase 1 and platelet-activating factor acetylohydrolase activity. Life Sci 2010;87:126-32.
28. Kujiraoka T, Iwasaki T, Ishihara M, Ito M, Nagano M, Kawaguchi A et al. Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus. J Lipid Res 2003;44:2006-14.
29. Yamamoto I, Fujitsu J, Nohnen S, Igarashi T, Motomura T, Inaba M et al. Association of plasma PAF acetylhydrolase gene polymorphism with IMT of carotid arteries in Japanese type 2 diabetic patients. Diabetes Res Clin Pract 2003;59:219-24.
30. Markakis KP, Koropouli MK, Grammenou-Savvoglou S et al. Implication of lipoprotein associated phospholipase A2 activity in oxLDL uptake by macrophages. J Lipid Res 2010;51:2191-201.